COPD in Germany: Use of Diagnostic Measures Including Blood Eosinophil Counts in Daily Practice

Abstract

Background Accumulating evidence on the role of blood eosinophils as a biomarker prompted the Global Initiative for Chronic Obstructive Lung Disease (GOLD) committee to refine the existing treatment algorithm by incorporating eosinophil counts into treatment recommendations. However, there is a lack of data on when, why and how frequently such blood tests and other measures are being performed by German private respiratory specialists.

Methods A questionnaire evaluating doctors’ opinions on the use of diagnostic measures at initial diagnosis and during follow-up, including blood eosinophil count in patients with COPD, was completed by 27 respiratory specialists. Medical records from the past 12 months of 251 patients treated by the same physicians were reviewed retrospectively to investigate the use of these measures.

Results Body plethysmography (100 % of doctors) and chest X-ray (96.3 %) were the most commonly used measures according to the doctor’s questionnaire; other measures were COPD assessment test (CAT; 85.2 %) and blood eosinophil count (81.5 %). The evaluation of patients’ medical records revealed that body plethysmography was performed in 72.7 %, the CAT in 61.8 % and chest X-ray in 40.6 % of patients. Blood eosinophil count was measured in 7.2 %.

Conclusions In line with the GOLD recommendations, these results confirm that lung function, imaging and patient-reported outcome questionnaires play a crucial role in managing COPD. Our analyses reveal that measurement of the blood eosinophil count gained importance due to physicians’ increased awareness of these cells as a useful biomarker. However, this test seems to be performed mainly for initial diagnosis and not on a regular basis.

Zusammenfassung

Einleitung Die zunehmende Evidenz zur Rolle der Eosinophilen im Blut als Biomarker veranlasste das Global Initiative for Chronic Obstructive Lung Disease (GOLD)-Komitee, den bestehenden Behandlungsalgorithmus zu verfeinern, indem die Bestimmung der Eosinophilenzahl in die Behandlungsempfehlungen aufgenommen wurde. Es fehlen jedoch Daten darüber, wann, warum und wie häufig solche Blutuntersuchungen und auch andere diagnostische Maßnahmen von pneumologischen Fachärzten in Deutschland durchgeführt werden.

Methoden Anhand eines Arztfragebogens wurde die fachärztliche Einschätzung von 27 Pneumologen zum Einsatz von diagnostischen Maßnahmen, einschließlich der Zahl der Eosinophilen, bei der Erstdiagnose und während des Verlaufs der COPD-Erkrankung evaluiert. Die medizinischen Aufzeichnungen von 251 Patienten dieser Ärzte wurden in einer 12-monatigen, retrospektiven Analyse ausgewertet, um die tatsächliche Anwendung dieser Maßnahmen zu untersuchen.

Ergebnisse Bodyplethysmografie (100 % der Ärzte) und Röntgen des Thorax (96,3 %) waren laut Arztfragebogen die Tests, die am häufigsten verwendet wurden. Weitere Maßnahmen waren der COPD Assessment-Test (CAT; 85,2 %) und die Messung der Zahl der Blut-Eosinophilen (81,5 %). Die retrospektive Auswertung der Patientenakten ergab, dass bei 72,7 % der Patienten eine Bodyplethysmografie, bei 61,8 % der CAT und bei 40,6 % eine Röntgenaufnahme des Thorax durchgeführt wurde. Die Eosinophilenzahl im Blut wurde in 7,2 % gemessen.

Schlussfolgerungen In Übereinstimmung mit den GOLD-Empfehlungen bestätigen diese Ergebnisse, dass Lungenfunktion, Bildgebung und der Einsatz von Fragebögen zur Abbildung der Lebensqualität eine entscheidende Rolle bei der Behandlung von COPD spielen. Unsere Analysen zeigen, dass die Messung der Eosinophilenzahl im Blut aufgrund des zunehmenden Bewusstseins der Ärzte für diese Zellen als nützliche Biomarker an Bedeutung gewonnen hat. Dieser Test scheint jedoch hauptsächlich zur Erstdiagnose und nicht während des Verlaufs der Erkrankung durchgeführt zu werden.

Publication History

Received: 27 July 2020

Accepted: 20 September 2020

Article published online:
11 December 2020

• References

• 1 Han MK, Agusti A, Calverley PM. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604 DOI: 10.1164/rccm.200912-1843CC.
• 2 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD). 2020 Im Internet (Stand: 16.6.2020): http://goldcopd.org/
• 3 Vogelmeier C, Buhl R, Burghuber O. et al. Guideline for the diagnosis and treatment of COPD patients – Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology. Pneumologie 2018; 72: 253-308 DOI: 10.1055/s-0043-125031.
• 4 European Medicine Agencies (EMA), Pharmacovigilance Risk Assessment Committee (PRAC). Reviews known risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease. Im Internet (Stand: 16.06.2020): https://www.ema.europa.eu/en
• 5 Suissa S, Patenaude V, Lapi F. et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036 DOI: 10.1136/thoraxjnl-2012-202872.
• 6 Price D, Yawn B, Brusselle G. et al. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013; 22: 92-100 DOI: 10.4104/pcrj.2012.00092.
• 7 Bafadhel M, Mc Kenna S, Terry S. et al. Acute exacerbations of chronic obstructive pulmonary disease identification of biological clusters and their biomarkers. Am J Resp Crit Care Med 2011; 184: 662-671 DOI: 10.1164/rccm.201104-0597OC.
• 8 Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker?. Lancet Respir Med 2017; 5: 747-759 DOI: 10.1016/S2213-2600(17)30217-5.
• 9 Pascoe S, Locantore N, Dransfield MT. et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435-442 DOI: 10.1016/S2213-2600(15)00106-X.
• 10 Siddiqui SH, Guasconi A, Vestbo J. et al. Blood Eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in COPD. Am J Respir Crit Care Med 2015; 192: 523-525 DOI: 10.1164/rccm.201502-0235LE.
• 11 Watz H, Tetzlaff K, Wouters EF. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016; 4: 390-398 DOI: 10.1016/S2213-2600(16)00100-4.
• 12 Chapman KR, Hurst JR, Frent SM. et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in COPD patients (SUNSET): A randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018; 198: 329-339 DOI: 10.1164/rccm.201803-0405OC.
• 13 Bafadhel M, Peterson S, De Blas MA. et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 2018; 6: 117-126 DOI: 10.1016/S2213-2600(18)30006-7.
• 14 Lipson DA, Barnhart F, Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018; 378: 1671-1680 DOI: 10.1056/NEJMoa1713901.
• 15 Pascoe S, Barnes N, Brusselle G. et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med 2019; 7: 745-756 DOI: 10.1016/S2213-2600(19)30190-0.
• 16 Kardos P, Vogelmeier C, Worth H. et al. A two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: The DACCORD observational study. Respir Med 2017; 124: 57-64 DOI: 10.1016/j.rmed.2017.02.007.
• 17 Criner RN, Labaki WW, Regan EA. et al. Mortality and exacerbations by Global Initiative for Chronic Obstructive Lung Disease groups ABCD: 2011 versus 2017 in the COPDgene cohort. Chronic Obstr Pulm Dis 2019; 6: 64-73 DOI: 10.15326/jcopdf.6.1.2018.0130.
• 18 Vestbo J, Vogelmeier CF, Small M. et al. Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population. Int J Chron Obstruct Pulmon Dis 2019; 14: 853-861 DOI: 10.2147/COPD.S189585.
• 19 Glaab T, Banik N, Trautmann M. et al. Guideline-conformity of outpatient COPD management by pneumologists. Pneumologie 2006; 60: 395-400 DOI: 10.1055/s-2006-932166.
• 20 Hellmann A, Hering T, Andres J. Expenditure on the care of COPD patients under everyday conditions in pneumological practices differentiated according to patients in chronic care and new patients and severity of the illness. Pneumologie 2018; 72: 437-445 DOI: 10.1055/s-0043-120365.
• 21 Greulich T, Ottaviani S, Bals R. et al. Alpha1-antitrypsin deficiency – diagnostic testing and disease awareness in Germany and Italy. Respir Med 2013; 107: 1400-1408 DOI: 10.1016/j.rmed.2013.04.023.
• 22 Gupta N, Pinto LM, Morogan A. et al. The COPD assessment test: a systematic review. Eur Respir J 2014; 44: 873-884 DOI: 10.1183/09031936.00025214.
• 23 Greulich T, Mager S, Lucke T. et al. Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort. Int J of COPD 2018; 3: 2999-3002 DOI: 10.2147/COPD.S165909.
• 24 Bafadhel M, Barnes N, Bourke S. et al. Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD? Abstract 1358, ERS International Congress, 28 Sept–2 Oct. Madrid, Spain: DOI: 10.1183/13993003.congress-2019.OA260